Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25029996 | 1.00 | MAPT (0.30) | MAPTHTR1ADRD2DRD1DRD4 | |
| SCHEMBL26058591 | 1.00 | MAPT (0.30) | MAPTHTR1ADRD2DRD1DRD4 | |
| SCHEMBL25030380 | 0.92 | DRD2 (0.33) | MAPTHTR1ADRD2DRD1DRD4 | |
| SCHEMBL25029513 | 0.92 | DRD2 (0.33) | MAPTHTR1ADRD2DRD1DRD4 | |
| SCHEMBL25029992 | 0.92 | DRD2 (0.33) | MAPTHTR1ADRD2DRD1DRD4 | |
| SCHEMBL26058593 | 0.89 | MAPT (0.31) | MAPTHTR1ADRD2DRD1DRD4 | |
| SCHEMBL26058592 | 0.89 | DRD2 (0.35) | MAPTDRD2HTR2ADRD3 | |
| SCHEMBL25029995 | 0.89 | MAPT (0.33) | MAPTHTR1ADRD2DRD1DRD4 | |
| SCHEMBL26042397 | 0.87 | MAPT (0.30) | MAPT | |
| SCHEMBL26204536 | 0.87 | MAPT (0.30) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161877-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR INTEGRIN AVB6-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |